Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead supports funding requests for innovative, high impact projects that align with its core therapeutic focus areas. The grant program emphasizes the importance of applications demonstrating a strong commitment to delivering specific services that the funded grant would support. Gilead funds both Patient Community Support and Medical & Scientific Support initiatives.
Patient Community Support focuses on increasing disease awareness and screening among at-risk populations to address disparities in care. Supported projects include education on prevention and care options, and the funded organizations range from patient advocacy groups to academic medical centers.
Medical & Scientific Support is geared towards continuing medical education for healthcare professionals to ensure they remain informed on the latest medical advances. This includes accredited and non-accredited CME programs, scientific conferences, and lecture series, with a diverse range of eligible organizations including medical universities and community health centers.
Additionally, Gilead has specific grantmaking priorities in Africa, where their work, alongside local partners, aims to expand access to high-quality, low-cost HIV treatment and support a range of activities within the therapeutic areas of HIV/AIDS and Viral Hepatitis. These activities include disease awareness and prevention, professional education, patient access to care, quality of care improvement, scientific capacity increase, and healthcare system strengthening. There are no minimum or maximum request amounts for funding, and applicants are encouraged to request what is necessary based on programmatic needs.